Technical Analysis for ABVC - ABVC Biopharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.48% | |
Stochastic Buy Signal | Bullish | -5.48% | |
Narrow Range Bar | Range Contraction | -5.48% | |
Wide Bands | Range Expansion | -5.48% | |
Gapped Up | Strength | -5.48% | |
Up 3 Days in a Row | Strength | -5.48% | |
Oversold Stochastic | Weakness | -5.48% | |
Doji - Bullish? | Reversal | 2.11% | |
Wide Bands | Range Expansion | 2.11% | |
Oversold Stochastic | Weakness | 2.11% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | 37 minutes ago |
Outside Day | 37 minutes ago |
Down 5% | 37 minutes ago |
Down 3% | 37 minutes ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | 37 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: 11/13/2024
ABVC Biopharma, Inc. Description
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Pancreatic Cancer Depression Major Depressive Disorder Myelodysplastic Syndrome Attention Deficit Hyperactivity Disorder Treatment Of Pancreatic Cancer Triple Negative Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.18 |
52 Week Low | 0.4053 |
Average Volume | 170,734 |
200-Day Moving Average | 0.88 |
50-Day Moving Average | 0.61 |
20-Day Moving Average | 0.60 |
10-Day Moving Average | 0.53 |
Average True Range | 0.06 |
RSI (14) | 48.72 |
ADX | 14.55 |
+DI | 20.03 |
-DI | 16.71 |
Chandelier Exit (Long, 3 ATRs) | 0.59 |
Chandelier Exit (Short, 3 ATRs) | 0.67 |
Upper Bollinger Bands | 0.76 |
Lower Bollinger Band | 0.43 |
Percent B (%b) | 0.4 |
BandWidth | 54.84 |
MACD Line | -0.02 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0035 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.60 | ||||
Resistance 3 (R3) | 0.60 | 0.59 | 0.60 | ||
Resistance 2 (R2) | 0.59 | 0.58 | 0.59 | 0.60 | |
Resistance 1 (R1) | 0.58 | 0.57 | 0.58 | 0.58 | 0.59 |
Pivot Point | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 |
Support 1 (S1) | 0.55 | 0.55 | 0.56 | 0.56 | 0.54 |
Support 2 (S2) | 0.54 | 0.55 | 0.54 | 0.54 | |
Support 3 (S3) | 0.53 | 0.54 | 0.54 | ||
Support 4 (S4) | 0.53 |